Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
307.08
+13.44 (4.58%)
Jan 21, 2025, 4:00 PM EST - Market closed
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for MDGL stock have an average target of 351.67, with a low estimate of 150 and a high estimate of 441. The average target predicts an increase of 14.52% from the current stock price of 307.08.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MDGL stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $390 → $400 | Strong Buy | Maintains | $390 → $400 | +30.26% | Jan 14, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $427 | Buy | Reiterates | $427 | +39.05% | Jan 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 20, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $194 → $236 | Hold | Maintains | $194 → $236 | -23.15% | Nov 5, 2024 |
| UBS | UBS | Strong Buy Maintains $411 → $441 | Strong Buy | Maintains | $411 → $441 | +43.61% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
174.89M
Revenue Next Year
517.59M
from 174.89M
Increased by 195.95%
EPS This Year
-24.12
from -19.99
EPS Next Year
-13.56
from -24.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 187.8M | 676.8M | 1.4B | |||
| Avg | 174.9M | 517.6M | 1.1B | |||
| Low | 154.6M | 289.6M | 508.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 287.0% | 170.1% | |||
| Avg | - | 196.0% | 103.1% | |||
| Low | - | 65.6% | -1.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -24.09 | -8.38 | 16.38 | |||
| Avg | -24.12 | -13.56 | 2.75 | |||
| Low | -24.02 | -25.82 | -21.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.